Peptide Association LLC is a for-profit company. We receive compensation from the clinical providers listed on this site. We are not an accrediting body, a licensing board, or a government-affiliated organization. See exactly how we make money.
Defensin HNP-1
Overview
Human neutrophil peptide 1 (HNP-1) is a 30-amino acid alpha-defensin produced by neutrophils as part of the innate immune response. It contains three stabilizing disulfide bonds and forms amphipathic structures that disrupt microbial membranes through electrostatic and hydrophobic interactions.
Mechanism of Action
HNP-1 exhibits antimicrobial activity against bacteria, fungi, and enveloped viruses, and also modulates immune cell function and inflammatory responses. As an endogenous peptide, it has been studied for potential therapeutic augmentation in immunocompromised states and chronic infections.
Research Summary & Key Findings
Preclinical studies have characterized HNP-1 antimicrobial mechanisms and immunomodulatory properties in vitro and in animal models. Elevated or reduced HNP-1 levels have been associated with various infectious and inflammatory diseases in observational clinical studies. No therapeutic clinical trials using exogenous HNP-1 administration have been conducted, and development challenges include synthesis cost and delivery optimization.
Clinical Status
Defensin HNP-1 is in the research phase with limited clinical data in humans. Current evidence is primarily derived from preclinical (animal or in vitro) studies.
Administration Routes
References
Primary literature
- PubMed: "Defensin HNP-1"
Peer-reviewed literature indexed by the National Library of Medicine.
- ClinicalTrials.gov: "Defensin HNP-1"
Registered interventional and observational studies, including status and phase.
- PubChem: "Defensin HNP-1"
Chemical structure, molecular properties, and bioactivity data.
Study-level citations for this compound are being verified against the primary sources before publication. The database queries above return the current indexed literature in the meantime.
Related Peptides in Antimicrobial
Enfuvirtide (Fuzeon)
FDA ApprovedA 36-amino acid synthetic peptide that inhibits HIV-1 entry into CD4+ T-cells by blocking the gp41-mediated membrane fus...
View detailsMagainin 2
Research PhaseMagainin 2 is a 23-amino acid antimicrobial peptide originally isolated from the skin of the African clawed frog Xenopus...
View detailsPexiganan (MSI-78)
In Clinical TrialsPexiganan is a 22-amino acid synthetic analog of magainin 2 designed to enhance antimicrobial potency and proteolytic st...
View detailsOmiganan
In Clinical TrialsOmiganan is a synthetic 12-amino acid cationic antimicrobial peptide derived from indolicidin, a naturally occurring pep...
View detailsNo lawful pathway today
Defensin HNP-1 is not FDA-approved and does not currently have a lawful prescription or compounding pathway in the United States, so there is nothing for us to sell you here and no consultation to book. That can change: eight peptides moved back to a lawful pathway in February 2026.
Tell me if the status changes
One email, only if this compound's regulatory standing actually moves. Not a newsletter, not a sales sequence.
Join the Association
Access exclusive peptide protocols, provider resources, and community support.
List Your PracticeDisclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed.